Matritech regulatory update

The FDA approved the NMP22 Test Kit to identify patients at risk for recurrence of bladder cancer. The test is based on the discovery that nuclear matrix proteins (NMPs) in cancer cells differ from those in normal cells. NMPS said it will begin sales by the end of the month. The company anticipates that a doctor would charge $50 for the test versus $300 for a cystoscopy. ...